Abstract
Background
Methods
Results
Notes
CONFLICTS OF INTEREST
One of the co-authors, Ji-Hyun Kim, is a current employee at Sanofi-Aventis Korea, but no potential conflict of interest was reported by the author.
This study was supported by Sanofi-Aventis Korea. Medical writing and editorial support in the preparation of this publication was provided by Satyendra Shenoy from Describe Scientific Writing & Communications who was paid for by Sanofi-Aventis Korea and Anahita Gouri and Rohan Mitra from Sanofi-Aventis Korea. The authors individually and collectively are responsible for all content and editorial decisions and received no payment from Sanofi-Aventis Korea directly or indirectly (through a third party) related to the development/presentation of this publication.
AUTHOR CONTRIBUTIONS
Conception or design: J.S.K., K.M.C., K.W.L., S.C.L., J.R.C., S.J.O., J.H.K., S.H.C. Acquisition, analysis, or interpretation of data: Y.S.Y., S.Y.L., J.S.K., K.M.C., K.W.L., S.C.L., J.R.C., S.J.O., J.H.K., S.H.C. Drafting the work or revising: Y.S.Y., S.H.C. Final approval of the manuscript: Y.S.Y., S.Y.L., J.S.K., K.M.C., K.W.L., S.C.L., J.R.C., S.J.O., J.H.K., S.H.C.
REFERENCES
Table 1
Characteristic | Risk category | Total (n=1,034) | ||||
---|---|---|---|---|---|---|
|
||||||
Low (n=1) | Moderate (n=47) | High (n=178) | Very high (n=747) | Non-assessablea (n=61) | ||
Age in years | 30.0 | 56.2±7.9 | 60.9±9.5 | 64.5±10.4 | 62.6±11.0 | 63.3±10.4 |
|
||||||
Gender | ||||||
Male | 0 | 12 (25.5) | 76 (42.7) | 455 (60.9) | 25 (41.0) | 568 (54.9) |
Female | 1 (100) | 35 (74.5) | 102 (57.3) | 292 (39.1) | 36 (59.0) | 466 (45.1) |
|
||||||
History of dyslipidemia | 1 (100) | 47 (100) | 167 (93.8) | 536 (72.1) | 45 (73.8) | 796 (77.0) |
|
||||||
Time in years since diagnosis of dyslipidemia | 1.0 | 4.1±3.0 | 5.1±3.6 | 5.0±3.7 | 4.2±2.8 | 4.9±3.6 |
|
||||||
Prevalence of CV risk factors | ||||||
Hypertensionb | 1 (100) | 22 (46.8) | 100 (56.2) | 569 (76.2) | 38 (62.3) | 730 (70.6) |
Lack of physical activityc | 1 (100) | 30 (63.8) | 104 (58.4) | 446 (59.7) | 40 (65.6) | 621 (60.1) |
Diabetesd | 0 | 0 | 140 (78.7) | 377 (50.5) | 0 | 517 (50.0) |
Regular alcohol consumptione | 0 | 4 (8.5) | 32 (18.0) | 143 (19.1) | 11 (18.0) | 190 (18.4) |
Familial history of CVDf | 0 | 7 (14.9) | 32 (18.0) | 137 (18.3) | 12 (19.7) | 188 (18.2) |
Current smokingg | 0 | 1 (2.1) | 19 (10.7) | 116 (15.5) | 8 (13.1) | 144 (13.9) |
|
||||||
CV comorbidities | ||||||
CAD | 0 | 0 | 0 | 424 (56.8) | 0 | 424 (41.0) |
ACS/MIh (n=424) | NA | NA | NA | 254 (59.9) | NA | 254 (59.9) |
PCIh (n=424) | NA | NA | NA | 246 (58.0) | NA | 246 (58.1) |
CABGh (n=424) | NA | NA | NA | 16 (3.8) | NA | 16 (3.8) |
Stroke | 0 | 0 | 0 | 140 (18.7) | 0 | 140 (13.5) |
CKDi | 1 (100.0) | 9 (19.1) | 9 (5.1) | 94 (12.6) | 5 (8.2) | 118 (11.4) |
CV, cardiovascular; CVD, cardiovascular disorder; CAD, coronary artery disease; ACS, acute coronary syndrome; MI, myocardial infarction; NA, not applicable; PCI, percutaneous intervention; CABG, coronary artery bypass graft; CKD, chronic kidney disease.
a Patients without a serious pathology classifying them as very high or high cardiovascular risk, and in whom the Systematic COronary Risk Evaluation (SCORE) could not be calculated due to missing data (most commonly baseline low-density lipoprotein cholesterol);
b Systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg or a previous history of hypertension;
c Patient is not regularly involved in moderate (walking/cycling/gardening) or strenuous exercise (jogging/football/vigorous swimming) for ≥4 hours each week;
F Coronary and/or vascular disease <55 years of age in male and <60 years in female first-degree relatives;
Table 2
Risk assessed by investigator | Risk category | Total (n=1,034) | ||||
---|---|---|---|---|---|---|
Low (n=1) | Moderate (n=47) | High (n=178) | Very high (n=747) | Non-assessablea (n=61) | ||
Low | 0a | 20 (42.6) | 39 (21.9) | 65 (8.7) | 14 (23.0) | 138 (13.3) |
Moderate | 1(100) | 23 (48.9)a | 41 (23.0) | 226 (30.3) | 39 (63.9) | 330 (31.9) |
High | 0 | 4 (8.5) | 82 (46.1)a | 306 (41.0) | 6 (9.8) | 398 (38.5) |
Very high | 0 | 0 | 16 (9.0) | 150 (20.1)a | 2 (3.3) | 168 (16.2) |
Table 3
Variable | Risk category | Total (n=1,034) | ||||
---|---|---|---|---|---|---|
|
||||||
Low (n=1) | Moderate (n=47) | High (n=178) | Very high (n=747) | Non-assessablea (n=61) | ||
Lipid-modifying treatment | ||||||
Statins | 1 (100) | 47 (100) | 169 (94.9) | 729 (97.6) | 58 (95.1) | 1,004 (97.1) |
Fibrates | 0 | 0 | 10 (5.6) | 27 (3.6) | 4 (6.6) | 41 (4.0) |
Omega-3 fatty acids | 0 | 2 (4.3) | 8 (4.5) | 29 (3.9) | 1 (1.6) | 40 (3.9) |
Cholesterol absorption inhibitors | 0 | 6 (12.8) | 6 (3.4) | 19 (2.5) | 0 | 31 (3.0) |
Others | 0 | 0 | 0 | 6 (0.8) | 0 | 6 (0.6) |
|
||||||
Patients receiving high-intensity statinsb | 0 | 2 (4.3) | 9 (5.3) | 66 (9.1) | 1 (1.7) | 78 (7.8) |
|
||||||
Patients receiving highest permissible dose of statins | 0 | 2 (4.3) | 15 (8.9) | 53 (7.3) | 4 (6.9) | 74 (7.4) |
|
||||||
Reason for not prescribing the highest dose of statins | ||||||
Assessed number of patients | 1 | 45 | 154 | 664 | 54 | 918 |
Physician satisfactionc | 0 | 35 (77.8) | 141 (91.6) | 550 (82.8) | 50 (92.6) | 776 (84.5) |
Medically inappropriated | 1 (100) | 9 (20.0) | 9 (5.8) | 154 (23.2) | 13 (24.1) | 186 (20.3) |
Statin intolerancee | 0 | 1 (2.2) | 4 (2.6) | 15 (2.3) | 0 | 20 (2.2) |